Efficacy of a Collagen Hemostatic Dressing After Tooth Extraction
Efficacy of a Collagen Topical Hemostatic Agent After Tooth Extraction: a Comparative Randomized Clinical Trial
2 other identifiers
interventional
38
1 country
2
Brief Summary
This study is a multicentric randomised (2 groups, ratio 1:1) Post Market Clinical Follow-up trial. 38 subjects (teeth) requiring a simple tooth extraction or multiple tooth extraction on the same quadrant and taking curative or preventive antithrombotic treatment will be included (19 in each group). The aim of the study is to assess the efficacy of ETIK COLLAGENE (Topical hemostatic collagen-product) on the hemostasis (time to stop bleeding) after tooth extraction. The hemostasis is measured by assessing the presence of bleeding within the first 8 minutes post-extraction. Group 1: intra-alveolar placement of ETIK COLLAGENE immediately after tooth extraction. Group 2: the alveolus is left empty after tooth extraction (the use of ETIK COLLAGENE is delayed 8 minutes after tooth extraction, before suture). Subjects will be followed-up to 7 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2022
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 13, 2021
CompletedFirst Posted
Study publicly available on registry
January 3, 2022
CompletedStudy Start
First participant enrolled
January 25, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 20, 2022
CompletedJune 1, 2022
May 1, 2022
4 months
December 13, 2021
May 30, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of time to hemostasis after tooth extraction
For each patient, the time to stop bleeding (expressed in minutes) is assessed as follows : every 30 seconds from the tooth extraction (T0) to 8 minutes post extraction, the oral surgeon observes the alveolus during 5 seconds and records the presence or absence of bleeding.
over 8 minutes after tooth extraction
Secondary Outcomes (4)
Rate of bleeding at 20 minutes
20 minutes after tooth extraction
Occurrence of secondary post-extraction bleeding
7 days
Level of pain after dental extraction by a numeric scale
At the end of the oral surgery, day 1, day 2, day 3
Number of adverse and serious adverse events
From the end of the oral surgery to Day 7
Study Arms (2)
Device under investigation
EXPERIMENTALintra-alveolar placement of the hemostatic dressing ETIK COLLAGENE immediately after tooth extraction.
Comparator
OTHERthe alveolus is left empty after tooth extraction.
Interventions
The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.
The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
Eligibility Criteria
You may qualify if:
- Male or female, age \> 18 years old,
- Patient undergoing a simple tooth extraction or multiple tooth extraction on the same quadrant,
- Patient taking curative or preventive antithrombotic treatment or patient with a moderate thrombocytopenia,
- Patient reachable after surgery,
- Signed informed consent form,
- Subject affiliated to a health insurance system, or is a beneficiary.
You may not qualify if:
- Known allergy to bovine collagen,
- Preoperative INR\<1.5 or \>3 or instable,
- Patient with high risk of bleeding, history of postoperative hemorrhagic complication,
- Treatment with bone resorption inhibitor, or patient irradiated at the cervico-facial level,
- Contraindication to anesthesia using articaine with 1:200,000 epinephrine,
- Clinical follow-up expected to be difficult,
- Presence of uncontrolled hypertension, uncompensated diabetes or other clinically relevant systemic alterations,
- Vulnerable subjects.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ACTEON Grouplead
- Slb Pharmacollaborator
Study Sites (2)
Faculté d'odontologie du CHU Nantes
Nantes, 44000, France
CSD Rennes
Rennes, 35000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Flora THIBAUT, DDS
Centre de soins dentaire CHU Rennes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- the participant will be blind from the treatment
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 13, 2021
First Posted
January 3, 2022
Study Start
January 25, 2022
Primary Completion
May 20, 2022
Study Completion
May 20, 2022
Last Updated
June 1, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share